"Anticoagulants" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that prevent BLOOD CLOTTING.
| Descriptor ID |
D000925
|
| MeSH Number(s) |
D27.505.954.502.119
|
| Concept/Terms |
Anticoagulants- Anticoagulants
- Anticoagulation Agents
- Agents, Anticoagulation
- Anticoagulant Agents
- Agents, Anticoagulant
- Anticoagulant Drugs
- Drugs, Anticoagulant
- Anticoagulant
|
Below are MeSH descriptors whose meaning is more general than "Anticoagulants".
Below are MeSH descriptors whose meaning is more specific than "Anticoagulants".
This graph shows the total number of publications written about "Anticoagulants" by people in this website by year, and whether "Anticoagulants" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 1 | 2 |
| 1998 | 0 | 1 | 1 |
| 1999 | 1 | 1 | 2 |
| 2000 | 2 | 1 | 3 |
| 2001 | 2 | 0 | 2 |
| 2002 | 1 | 6 | 7 |
| 2003 | 3 | 0 | 3 |
| 2004 | 6 | 0 | 6 |
| 2005 | 4 | 2 | 6 |
| 2006 | 4 | 4 | 8 |
| 2007 | 4 | 6 | 10 |
| 2008 | 6 | 7 | 13 |
| 2009 | 3 | 3 | 6 |
| 2010 | 8 | 4 | 12 |
| 2011 | 9 | 3 | 12 |
| 2012 | 15 | 7 | 22 |
| 2013 | 15 | 5 | 20 |
| 2014 | 10 | 8 | 18 |
| 2015 | 10 | 9 | 19 |
| 2016 | 10 | 10 | 20 |
| 2017 | 17 | 10 | 27 |
| 2018 | 11 | 2 | 13 |
| 2019 | 9 | 9 | 18 |
| 2020 | 19 | 10 | 29 |
| 2021 | 10 | 23 | 33 |
| 2022 | 4 | 27 | 31 |
| 2023 | 0 | 23 | 23 |
| 2024 | 18 | 15 | 33 |
| 2025 | 8 | 6 | 14 |
| 2026 | 8 | 3 | 11 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anticoagulants" by people in Profiles.
-
Short and long-term outcomes of intermediate-high risk pulmonary embolism treated with catheter-directed reperfusion therapy versus anticoagulation. Respir Med. 2026 Nov; 263:109186.
-
Perspectives: what we are learning from factor XI/factor XIa inhibitor trials. Res Pract Thromb Haemost. 2026 Sep; 10(Suppl 3):106936.
-
Efficacy and safety of anticoagulation for pediatric cerebral sinovenous thrombosis: systematic review and meta-analysis. Res Pract Thromb Haemost. 2026 Aug; 10(6):106905.
-
Evaluating the potential of factor XI/factor XIa inhibitors to address unmet anticoagulation needs in critical patient populations. Res Pract Thromb Haemost. 2026 Sep; 10(Suppl 3):106624.
-
Management of Patients at Risk of Ischemic Stroke With Left Ventricular Systolic Dysfunction in the Absence of Intracardiac Thrombus: A Scientific Statement From the American Heart Association. Stroke. 2026 Aug; 57(8):e437-e454.
-
ASH/ISTH 2026 guidelines for anticoagulant prophylaxis in pediatric patients at risk of venous thromboembolism. Blood Adv. 2026 06 23; 10(12):4303-4333.
-
Venous thromboembolic events in traumatic brain injury. Does timing of prophylaxis matter? A single-center retrospective cohort study. Proc (Bayl Univ Med Cent). 2026 Sep; 39(5):809-813.
-
Metabolic complications of citrate anticoagulation in continuous renal replacement therapy (crrt): a delphi consensus on indications, monitoring and management. Crit Care. 2026 May 13; 30(1).
-
Measuring up: the need for new assays for factor (F)XI/FXIa inhibitor therapies. Res Pract Thromb Haemost. 2026 Sep; 10(Suppl 3):106640.
-
2026 American Association for Thoracic Surgery Expert Consensus Document: Diagnosis and management of heparin-induced thrombocytopenia in patients who undergo cardiac surgery. J Thorac Cardiovasc Surg. 2026 09; 172(3):487-509.e3.